News RA pill setback spoils Lilly’s growth story Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by grow
News AbbVie looks beyond Humira as RA pill meets phase 3 targets Upadacitinib hopes drug will reduce reliance on Humira.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
